REQUEST AN APPOINTMENT OR BOOK A CONSULANT – Sargam.dange.18@gmail.com
INTRODUCTION-
Alcoholism results from an interplay between genetic and environmental factors, and is linked to brain defects and associated cognitive, emotional, and behavioral impairments. A confluence of findings from neuroimaging, physiological, neuropathological, and neuropsychological studies of alcoholics indicate that the frontal lobes, limbic system, and cerebellum are particularly vulnerable to damage and dysfunction. An integrative approach employing a variety of neuroscientific technologies is essential for recognizing the interconnectivity of the different functional systems affected by alcoholism. In that way, relevant experimental techniques can be applied to assist in determining the degree to which abstinence and treatment contribute to the reversal of atrophy and dysfunction.
The alcohol withdrawal syndrome is a well‐known condition occurring after intentional or unintentional abrupt cessation of heavy/constant drinking in patients suffering from alcohol use disorders (AUDs). AUDs are common in neurological departments with patients admitted for coma, epileptic seizures, dementia, polyneuropathy, and gait disturbances. Nonetheless, diagnosis and treatment are often delayed until dramatic symptoms occur. The purpose of this review is to increase the awareness of the early clinical manifestations of AWS and the appropriate identification and management of this important condition in a neurological setting.
An estimated 76.3 million people worldwide have alcohol use disorders (AUDs), and these account for 1.8 million deaths each year. It is estimated that up to 42% of patients admitted to general hospitals, and one‐third of patients admitted to hospital intensive care units (ICU) have AUD. Alcohol withdrawal syndrome (AWS) is a well‐known condition occurring after intentional or unintentional abrupt cessation of heavy/constant drinking, and it occurs in about 8% of hospitalized AUD inpatients. Severe AWS more than doubles the length of stay and frequently requires treatment at the ICU. A complicated AWS includes epileptic seizures and/or delirium tremens (DT), the occurrence of which may be as high as 15% in AUD patients., Delirious patients show high rates of comorbidities, and their mortality rate is comparable to patients having severe malignant diseases. However, with early detection and appropriate treatment, the expected mortality is in the range of 1% or less.
AUDs are common in patients referred to neurological departments, admitted for coma, epileptic seizures, dementia, polyneuropathy, and gait disturbances. Nonetheless, diagnosis and treatment are often delayed until dramatic symptoms occur. The purpose of this review is to increase the awareness of the early clinical manifestations of AWS and the appropriate identification and management of this important condition in a neurological setting.

Types of Alcohol-Related Neurologic Disorders
There are several neurological diseases that can be caused by alcohol abuse, including fetal alcohol syndrome, dementia, and some symptoms associated with alcohol withdrawal. Alcohol-related neurological diseases include:
- Alcoholic cerebellar degeneration: This is one of the more common forms of cerebellar ataxia, or loss of tissue mass in the brain. The most common symptom associated with cerebellar degeneration involves the loss of the ability to walk over a period of months or years. The condition also affects eye movements, gait or pace, and, rarely, loss of muscle coordination in the upper body. Cerebellar degeneration is caused by malnutrition, but the main cause in most of the Western world is alcohol abuse.
- Alcoholic myopathy: About 33 percent of people struggling with alcohol use disorder develop alcoholic myopathy. This condition involves the breakdown of proximal muscles, which are found in the arms, shoulders, thighs, and upper legs – skeletal muscles found nearest the body’s trunk. Symptoms include:
- Muscle pain, tenderness, swelling, and weakness, which may appear after a binge or when the person wakes from an alcoholic stupor
- Cardiomyopathy, or weakening and drooping of the heart muscle so it does not pump blood efficiently
- Renal damage or failure, when the toxins from muscle breakdown flood the kidneys to the point that the organs can no longer effectively filter them out
Alcoholic neuropathy: Although it is unclear what exactly causes the condition, alcoholic neuropathy is a deadening of nerves throughout the peripheral nervous system, so the person will feel tingling or burning sensations and numbness, and have trouble with basic functions like walking, internal body temperature regulation, and bowel or bladder function. The causes of alcoholic neuropathy likely involve poisoning of the nerves due to high-volume consumption of alcohol and poor nutrition associated with problem drinking. Symptoms of alcoholic neuropathy include:
- Numbness in the extremities, including the arms and legs
- The feeling of “pins and needles” or other abnormal sensations
- Pain or burning in the arms and legs
- Muscle problems, including cramps, weakness, spasms, or aching sensations
- Heat intolerance due to poor regulation, especially after exercise
- Incontinence, trouble urinating, or other bladder problems
- Diarrhea or constipation
- Nausea and vomiting
- Trouble speaking or swallowing
- Unsteady gait, stumbling, or lack of balance
Delirium tremens: When a person suddenly stops drinking after abusing alcohol for many years, they are at risk of developing alcohol withdrawal syndrome, or delirium tremens (DT). The body has developed a physical dependence on alcohol to manage brain function, so when the substance is suddenly removed, life-threatening side effects can develop. These include:
- Severe confusion or delirium
- Physical tremors
- Changes in thinking or memory
- Extreme agitation and irritability
- Intense excitement, fear, or paranoia
- Hallucinations
- Sudden bursts of energy
- Stupor, or being awake but unresponsive
- Seizures or convulsions
Fetal alcohol spectrum disorders: While many alcohol-related neurological conditions occur in people who consume too much alcohol, fetal alcohol spectrum disorders (FASDs) occur in babies or children, and may lead to life-long developmental delays, emotional or behavioral abnormalities, or trouble thinking or learning. Women who consume alcohol while pregnant put their children at risk for FASDs. Types of FASDs include:
- Fetal alcohol syndrome (FAS): Fetal death is the most extreme outcome from a woman struggling with AUD or problem drinking during pregnancy; other forms of FAS include abnormal facial features, growth problems, and developmental differences or disabilities in the central nervous system (CNS). People who live with FAS may have trouble with their memory, attention, communication skills, learning abilities, hearing, and/or vision.
- Alcohol-related neurodevelopmental disorder (ARND): With this disorder, children and adults have intellectual disabilities, behavioral struggles, and trouble learning.
- Alcohol-related birth defects: These involve physical problems, including damage to the heart, kidneys, hearing, or bones during fetal development.
Wernicke-Korsakoff syndrome: This condition is a combination of two forms of brain disease, Wernicke’s encephalopathy and Korsakoff syndrome. Both of these conditions are triggered by a loss of thiamine, or vitamin B12, which is most often caused by problem drinking. When a person struggles with heavy drinking or alcohol use disorder, they are more likely to drink alcohol than eat regular meals, and the body will struggle to absorb nutrients from food over time.Symptoms of Wernicke’s encephalopathy include:
- Reduced mental activity
- Confusion
- Ataxia, starting with muscle tremors in the legs and leading to loss of muscle control overall
- Abnormal eye movements
- Double vision
- Eyelid drooping
- Withdrawal symptoms if the person stops drinking
Korsakoff syndrome’s symptoms include:
- Trouble forming new memories
- Trouble remembering old memories, leading to fabrication of events or people
- Other forms of severe memory loss
- Hallucinations, especially visual or auditory
In some cases, one or both syndromes will clear up on their own; however, in 25 percent of Wernicke-Korsakoff syndrome cases, the problem does not stop on its own and is likely to get worse. This is especially true if the person does not stop drinking alcohol and get treatment.
Pathophysiology
Ethanol is a central nervous system depressant that produces euphoria and behavioral excitation at low blood concentrations due to increased glutamate binding to N‐methyl‐D‐aspartate (NMDA) receptors; at higher concentrations, it leads to acute intoxication by potentiation of the gamma‐aminobutyric acid (GABA) effects, particularly in receptors with delta subunits. The local distribution of these subunits explains why the cerebellum, cortical areas, thalamic relay circuitry, and brainstem are the main networks that mediate the intoxicating effects of alcohol. Prolonged alcohol use leads to the development of tolerance and physical dependence, which may result from compensatory functional changes by downregulation of GABA receptors and increased expression of NMDA receptors with production of more glutamate to maintain central nervous system (CNS) transmitter homeostasis.
Abrupt cessation of chronic alcohol consumption unmasks these changes with a glutamate‐mediated CNS excitation resulting in autonomic overactivity and neuropsychiatric complications such as delirium and seizures. The latter are usually of generalized tonic–clonic type and are mediated largely in the brainstem by abrogation of the tonic inhibitory effect of the GABAergic delta subunits. Therefore, the trigger zone of these seizures is distinct from that believed to be responsible for seizures in the context of epilepsy, and this may explain why epileptiform activity is rarely observed in the EEG after alcohol withdrawal seizures. As upregulation of NMDA receptors as well as reduced GABA‐A receptor inhibition largely explain the clinical symptoms, the therapeutic approach to AWS mainly targets these mechanisms. Dopamine is another neurotransmitter involved in alcohol withdrawal states. During alcohol use, increase in dopamine positively influences the reward system thereby maintaining abuse. In withdrawal, increase in dopamine levels contributes to the clinical manifestations of autonomic hyperarousal and hallucinations. Moreover, polymorphisms in the dopamine receptor 2 gene seem to influence not only AUD but also the clinical manifestation of alcohol withdrawal symptoms. In combination with increased glutamate and norepinephrine, it may also cause the elongation of the QT interval in people who have active epilepsy; this can increase the risk of sudden unexpected death in epilepsy (SUDEP).Another excitotoxic compound that is increased in AUD is homocysteine. During active drinking, there is an increase in homocysteine through stimulation of the NMDA receptors. In withdrawal, excitotoxicity is induced by further raise in homocysteine via rebound activation of glutamatergic neurotransmission.

Clinical spectrum
AWS represents a group of symptoms that usually arise 1–3 d after the last drink. Sometimes, the symptoms are already present when the alcohol blood level is above 0 (0.5‰ or even more). The Diagnostic and Statistical Manual of Mental Disorders (DSM‐5) outlines diagnostic criteria for AWS using two main components so that the AWS is diagnosed when the following two conditions are met:
- A clear evidence of cessation or reduction in heavy and prolonged alcohol use.
- The symptoms of withdrawal are not accounted for by a medical or another mental or behavioral disorder.
| Autonomic symptoms | Motor symptoms | Awareness symptoms | Psychiatric symptoms |
|---|---|---|---|
| Tachycardia | Hand tremor | Insomnia | Illusions |
| Tachypnea | Tremulousness of body | Agitation | Delusions |
| Dilated pupils | Seizures | Irritability | Hallucinations |
| Elevated blood pressure | Ataxia | Delirium | Paranoid ideas |
| Elevated body temperature | Gait disturbances | Disorientation | Anxiety |
| Diaphoresis | Hyper‐reflexia | Affective instability | |
| Nausea/vomiting | Dysarthria | Combativeness | |
| Diarrhea | Disinhibition |
The alcohol withdrawal syndrome is a dynamic and complex process. For this reason, there have been many attempts to classify symptoms of AWS either by severity or time of onset to facilitate prediction and outcome. In early stages, symptoms usually are restricted to autonomic presentations, tremor, hyperactivity, insomnia, and headache. In minor withdrawal, patients always have intact orientation and are fully conscious. Symptoms start around 6 h after cessation or decrease in intake and last up to 4–48 h (early withdrawal, Hallucinations of visual, tactile or auditory qualities, and illusions while conscious are symptoms of moderate withdrawal. They can last up to 6 d. The appearance of acute symptomatic seizures may emerge 6–48 h after the last drink. Delirium tremens (DT, onset 48–72 h after cessation of drinking) represents characteristics of severe withdrawal that may last for up to 2 weeks (late withdrawal)
The alcohol withdrawal seizure is a symptom occurring primarily during the early phase of withdrawal and is characterized by reduction in the seizure threshold. More than 90% of acute symptomatic seizures emerge within 48 h of cessation of prolonged drinking. Seizures frequently occur in the absence of other signs of the AWS. More than half of the individuals present with repeated seizures, and in up to 5%, they may progress to status epilepticus. More than 50% of withdrawal seizures are associated with concurrent risk factors such as prior epilepsy, structural brain lesions, or use of other drugs. It is remarkable that the development of acute symptomatic seizures during an alcohol withdrawal episode is associated with a fourfold increase in the mortality rate that is due to complications of severe AUD rather than a direct effect of seizures. The appearance of a withdrawal seizure represents a strong risk factor for progression into a severe withdrawal state with following development of DT in up to 30% of cases. Unprovoked seizures occurring later than 48 h after the last drink suggest other causes such as head trauma or combined drug withdrawal effects.
Delirium is a clinical syndrome of acute onset characterized by a global confusional state, perceptual abnormalities, and somatic symptoms of vegetative or central nervous presentation. Hallucinosis represents a unique form of withdrawal‐related psychosis which can begin even while the person is continuing to use alcohol or after cessation of drinking. The sensorium is clear in the beginning, but it often evolves into the syndrome of DT, a specific type of delirium typically associated with psychomotor agitation (hyperactive delirium) which emerges during the late withdrawal phase. Delirium can also manifest as a hypoactive state with decreased arousal and psychomotor activity, which is associated with a worse prognosis, delayed diagnosis and treatment as well as later complications. In cases of hypoactive delirium, comorbid or other medical illnesses must be ruled out. This is especially important in patients who have not had a previous history of DT.
| Hyponatremia | Due to poor oral intake, dehydration, and uremia; frequently presenting as hypoactive delirium |
| Hepatic encephalopathy | Jaundice, hematemesis, melena, icterus, flapping tremor, ascites, sleep–wake reversal |
| Pneumonia | Fever, cough, low arterial blood oxygen saturation, delirium before cessation of alcohol use |
| Encephalitis/Meningitis | Fever, meningeal signs, and focal neurological deficits; MRI/CSF abnormalities |
| Head injury | Being found unconscious, ear or nose bleeding, pinpoint pupils, focal neurological deficits |
| Thyrotoxicosis | History of thyroid illness; thyromegaly, exophthalmos, lagophthalmos |
| Lithium intoxication | History of psychiatric illness, drug overuse, diarrhea, fever, use of NSAID or diuretics |
| Atropine/Tricyclic intoxication | Fever, hot dry skin, dilated pupils |
| Psychosis | Hallucinations/delusions of long‐standing duration, absence of clouding of sensorium |
| Antidepressant intoxication | Use of SSRI; diarrhea, myoclonus, jitteriness, seizures, altered sensorium |
| Subacute encephalopathy with seizures in AUD | Several days after alcohol cessation; complex/simple partial seizures with reversible motor deficits; in EEG focal slowing, periodic lateralized discharges; MRI with reversible T2w flair hyperintensities |
In summary, physical examination and investigations should be directed toward detecting signs of intoxication, seizures, hallucinations, and delirium tremens as well as Wernicke’s encephalopathy (one or more symptoms of ataxia, amnesia, and ophthalmoplegia). Apart from neuropsychiatric symptoms, physical injury or medical problems including aspiration pneumonia, dehydration, and electrolyte imbalance should be taken into account.
Biomarkers
In several studies, possible predictors for the development of a severe AWS have been investigated. Medical history and laboratory biomarkers are the two most important methods for the identification of patients at high risk. It appears that the most robust predictor for an incident occurrence of DT or seizures is a history of a similar event.Clinical findings such as elevated heart rate, systolic blood pressure, and temperature are all easily verifiable in the initial patient assessment, although their predictive value to identify patients with AWS who are more likely to develop DT is not high. In a patient with impaired consciousness, laboratory markers represent helpful tools to confirm the suspected clinical diagnosis of an AUD.
Markers useful in the emergency setting
The quantitative, measurable detection of drinking is important for the successful treatment of AUD. Therefore, the importance of direct and indirect alcohol markers to evaluate consumption in the acute clinical setting is increasingly recognized. he detection of ethanol itself in different specimens is still a common diagnostic tool to prove alcohol consumption. Alcohol ingestion can be measured using a breath test. Although ethanol is rapidly eliminated from the circulation, the time for detection by breath analysis is dependent on the amount of intake as ethanol depletes according to a linear reduction at about 0,15‰/1 h. Alcohol use can alternatively be detected by direct measurement of ethanol in blood or urine. The time course of the ethanol concentration in the blood after the ingestion of an alcoholic beverage is controlled by its pharmacokinetics that represents an interplay between the kinetics of absorption, distribution, and elimination and is thus important in determining the pharmacodynamic responses to alcohol. There is a large degree of variability in alcohol metabolism as a result of both genetic and environmental factors.
| Ethanol | BreathBloodUrine | <6 h | 5–24 hdepletion 0,15‰/1 h | ~ 90%/~ 95% | Conversion factor breath alcohol:blood alcohol 1:2100 within 2–5 h after the last drink | |
| Hypokalemia | Blood | <6 h | Days to weeks | ~ 47%/~ 90% | Serum levels <2,5 mmol/L indicate severe AUD | |
| Thrombocytopenia | Blood | <6 h | 7–12 d | ~ 69%/~ 75% | High NPV, low PPV; rebound thrombocytosis after cessation of alcohol abuse | |
| Mean corpuscular volume | Blood | <6 h | 4 mo | ~ 80%/~ 60% | Dose‐dependent increase | |
| γ‐glutamyltransferase | Blood | <6 h | 2–8 wk | ~ 80%/~ 65% | Severe AUD with liver damage | |
| Ratio AST/ALT >2 | Blood | <6 h | AST 18 hALT 36 h | ~ 50%/~ 80% | Severe AUD, marker of liver damage |
Apart from ethanol itself, indirect markers of AUD are widely available and mostly part of routine laboratory testing. Severe AWS involves changes in electrolytes, especially potassium that is due to increased catecholamine activity with activation of the sodium–potassium ATPase pump and elevated vasopressin. Hypokalemia is not specific for alcohol consumption but is frequently reported to be associated with DT or seizures. The same applies to thrombocytopenia (with high negative predictive value) that additionally is predictive of an incident occurrence of DT and seizures. More indirect markers, such as AST, ALT, γGT, and MCV, are widely available and relatively inexpensive, but their predictive value is restricted because of low specificity. The interpretation of elevated values has to take into account other influencing factors including gender, age, comorbid disorders, and medication that also may increase these markers.
REQUEST AN APPOINTMENT OR BOOK A CONSULANT – Sargam.dange.18@gmail.com
Additional markers to detect AUD
Further biomarkers for non‐emergency cases or in the event of forensic questions are listed in Table . Carbohydrate‐deficient transferrin (CDT) is the most available and studied biomarker and has a high specificity for severe AUD. CDT values are not markedly influenced by medications except by immunosuppressants. The main disadvantage is the relatively low sensitivity making this parameter unsuitable as a screening tool. As CDT, γGT, and MCV are connected with AUD by different pathophysiological mechanisms, a combination of these parameters will further improve their diagnostic value.
| Carbohydrate‐deficient transferrin | Blood | >6 h | 2–4 wk | ~ 98%/~ 70% | Severe AUD | 24, 37 |
| Ratio γGT:CDT | Blood | >6 h | 2–3 wk | ~ 92%/~ 84% | Severe AUD | 24, 32 |
| Ethylglucuronid | Bloodurinehair | >6 h | 8 h20–80 h3 mo | ~ 99%/~ 89% | Values dependent on creatinine clearance | 31, 37 |
| Ethylsulfate | Bloodurine | >6 h | 8 h36–78 h | ~ 99%/~ 89% | Values dependent on creatinine clearance | 31, 37 |
| Phosphatidylethanol | Blood | >6 h | 4 wk | ~ 99%/~ 98% | Detection also available for dry blood spots | 27, 31, 42, 53 |
| Fatty acid ethyl esters | Bloodhair | >6 h | 24 h3 mo | ~ 97%/~ 77% | Combined measurement of ethylglucuronide and fatty acid ethyl esters in hair increases accuracy of interpretation | 27, 31, 44, 54 |
| 5‐hydroxytryptophol:5‐hydroxyindole‐3‐acetic acid | Urine | >6 h | 24 h | ~ 99%/~ 77% | Ratio >20 marker for recent alcohol intake | 47, 48 |
| Whole blood acetaldehyde | Blood | >6 h | 4 wk | ~ 93%/~ 78% | False‐positive results in diabetics | 55 |
| Total sialic acid | Blood | >6 h | Several weeks | ~ 95%/~ 81% | Glycoconjugate metabolite | 37, 44, 56 |
| Homocysteine | Blood | >6 h | Several weeks | ~ 61%/~ 72% | Cutoff ~24 μmol |
Apart from indirect markers for AUD, more specific alternatives focus on metabolic markers comprising direct products of alcohol degradation, that is, phosphatidylethanol (Peth), ethylglucuronide (EtG), ethylsulfate (EtS), and fatty acid ethyl esters (FAEE). Their presence is closely connected to alcohol consumption, and the well‐known CDT as well as sialic acid and EtG are the result of alcohol‐induced glycoconjugate metabolites. The highest sensitivity of up to 99% was observed for Peth that showed a rapid decrease at the beginning of withdrawal, a slow decline after the first few days, and persistence at low levels beyond 19d of abstinence. Apart from biomarkers detected in blood and urine samples, saliva is a promising and easy accessible material to detect glycomarkers of oxidative stress, but the reproducibility and validity in Peth has to be proven for clinical routine application. As an antibody based flash test is available for detection of EtG in urine with good sensitivity and specificity, this parameter is the most promising one to be integrated in routine laboratory settings and in screening of patients at risk to develop AWS.
As long as ethanol is metabolized, the metabolism of serotonin is shifted from formation of 5‐hydroxyindole‐3‐acetic acid (5‐HIAA) toward 5‐hydroxytryptophol (5‐HTOL). The 5‐HTOL/5‐HIAA ratio increases appreciably in urine after alcohol intake and is a promising marker for recent alcohol intake with a short window of detection. Until now, it has not found its way into clinical routine because of costly detection assays.
Recent investigations pointed out that homocysteine levels on admission might be a useful screening method for the risk of seizures in AWS, particular in combination with CDT. Several days after alcohol abstinence, homocysteine plasma levels decrease to normal. Homocysteine levels are influenced by nutritional status, gender, and age. Its metabolism is dependent on the enzyme 5,10‐methylenetetrahydrofolate reductase (MTHFR). The single‐nucleotide polymorphism MTHFR C677T elevates plasma homocysteine levels. Lutz et al. investigated two groups of patients with AWS and found this polymorphism to be related to higher occurrence of withdrawal seizures in the Western European population.
ALCOHOL AT A NEUROTRANSMITTER LEVEL
Alcohol’s central nervous system (CNS) effects are mediated through actions on a variety of neurotransmitters. There is a complex interplay between excitatory and inhibitory systems . The numerous transmitters involved in alcohol’s action explain its diverse effects and the large number of drug interactions with both prescribed and illicit drugs.
Alcohol and neurotransmitters
| • Dopamine: alcohol increases dopamine use in the nucleus accumbens, mediating its pleasurable effects via the common reward pathway of the mesolimbic system |
| • Noradrenaline: alcohol release of noradrenaline (norepinephrine) contributes to the enlivening and activating “party” effects of alcohol |
| • Endogenous opioids: Alcohol’s analgesic, pleasure, and stress reducing functions are opioid related |
| • GABA: Alcohol can potentiate GABA (γ aminobutyric acid) activity through certain subunits of the GABA A receptor. This accounts for alcohol’s anxiolytic and ataxic actions, and partially for amnesia and sedation. |
| • Glutamate: Alcohol acts to block the excitatory NMDA (N-methyl-d-aspartate) receptor, opposing glutamate causing amnesia and other cerebral depressant effects |
| • Serotonin: Alcohol’s stimulation of 5HT3 (5-hydroxytryptamine 3) provides the nausea associated with alcohol use. Serotonin may also be linked to the pleasurable effects of alcohol and differing brain serotonin levels may distinguish between anxious and aggressive alcohol users |
REQUEST AN APPOINTMENT OR BOOK A CONSULANT – Sargam.dange.18@gmail.com






























